Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald A Berry

Showing results (101-110 of 197) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et alKevin S Hughes, Lauren A Schnaper, Jennifer R Bellon, et al.
JAMA|April 13, 2006
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry, Constance Cirrincione, I Craig Henderson, et al.
JAMA Oncology|October 8, 2020
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysisNicholas J Short, Shouhao Zhou, Chenqi Fu, et al.
British Journal of Haematology|June 19, 2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaSusan O'Brien, David A Rizzieri, Norbert Vey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancerThomas B Julian, Peter Blumencranz, Kenneth Deck, et al.
The Lancet. Oncology|May 9, 2014
Addressing overdiagnosis and overtreatment in cancer: a prescription for changeLaura J Esserman, Ian M Thompson, Brian Reid, et al.
JAMA Oncology|February 26, 2016
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-AnalysisKristine R Broglio, Melanie Quintana, Margaret Foster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group BBlase N Polite, Constance Cirrincione, Gini F Fleming, et al.
Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemiaFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Pageof 20

Showing results (101-110 of 197) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et alKevin S Hughes, Lauren A Schnaper, Jennifer R Bellon, et al.
JAMA|April 13, 2006
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry, Constance Cirrincione, I Craig Henderson, et al.
JAMA Oncology|October 8, 2020
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysisNicholas J Short, Shouhao Zhou, Chenqi Fu, et al.
British Journal of Haematology|June 19, 2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaSusan O'Brien, David A Rizzieri, Norbert Vey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancerThomas B Julian, Peter Blumencranz, Kenneth Deck, et al.
The Lancet. Oncology|May 9, 2014
Addressing overdiagnosis and overtreatment in cancer: a prescription for changeLaura J Esserman, Ian M Thompson, Brian Reid, et al.
JAMA Oncology|February 26, 2016
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-AnalysisKristine R Broglio, Melanie Quintana, Margaret Foster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group BBlase N Polite, Constance Cirrincione, Gini F Fleming, et al.
Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemiaFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Pageof 20